HCPCS Q0155: Dronabinol (Syndros) 0.1 mg Oral Anti‑emetic
HCPCS Level II code Q0155 describes a single-unit dose of dronabinol (Syndros) 0.1 mg oral provided as an FDA‑approved prescription anti‑emetic intended for use as a complete therapeutic substitute for an intravenous anti‑emetic at the time of chemotherapy treatment; the service is an oral anti‑emetic medication administration used during chemotherapy sessions and the typical site of service is the outpatient oncology infusion clinic or chemotherapy treatment area with a dosing regimen not to exceed 48 hours.
For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.
Customize your policy alerts
Sign up for hcpcs Q0155 policy alerts
Get alerted when payer policies referencing Q0155 are released or updated.
Monitor payer policy activity